Shares of Alexion Pharmaceuticals (ALXN) were climbing over 2.3% in mid-morning trading on Tuesday after the biopharmaceutical firm secured FDA approval for its Soliris, a treatment for adult patients with generalized myasthenia gravis (gMG).

The treatment is approved for patients with gMG who are anti-acetylcholine receptor (AchR) antibody-positive.

Myasthenia gravis is a chronic condition that causes muscles to tire and weaken easily.

In a Phase 3 REGAIN study, Soliris proved beneficial for patients with anti-AchR antibody-positive gMG who had previously "failed immunosuppressive treatment and continued to suffer from significant unresolved disease symptoms," Alexion said. These symptoms included difficulties with talking, walking, swallowing and breathing.

"Today's approval is a significant milestone for Alexion and, more importantly, for the subset of patients with anti-AchR antibody-positive gMG who continue to suffer from significant unresolved disease symptoms despite existing treatment options," said John Orloff, M.D., Executive VP and Head of Research & Development at Alexion. 

More of What's Trending on TheStreet:

More from Stocks

Facebook Stock Slides Another 3% as Woes Continue

Facebook Stock Slides Another 3% as Woes Continue

Chart of the Day: How Jerome Powell Could Shift the Semiconductor Landscape

Chart of the Day: How Jerome Powell Could Shift the Semiconductor Landscape

Flashback Friday: Nvidia Is the Ultimate Chip and Dip

Flashback Friday: Nvidia Is the Ultimate Chip and Dip

Dow Ends Higher on Dovish Trump Tariff Comments; Nasdaq Falls

Dow Ends Higher on Dovish Trump Tariff Comments; Nasdaq Falls

How to Play Semiconductors Amid Nvidia's Crash, Cycle Pressure

How to Play Semiconductors Amid Nvidia's Crash, Cycle Pressure